Immunotherapy and targeted drugs for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–75 years old
- You have advanced or metastatic triple-negative breast cancer (ER, PR, and HER2 all negative) confirmed by biopsy
- Your cancer has not been treated with chemotherapy or immunotherapy for advanced disease (prior adjuvant/neoadjuvant therapy is okay if it's been ≥6 months since you finished)
- You have at least one measurable tumor and are expected to live at least 3 months
- Your organs (blood counts, liver, kidneys) are working well enough for treatment
- You cannot be pregnant, breastfeeding, or planning pregnancy during the study and for 4 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
Hear when a new TNBC, Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.